GSK Investigational Site

Schwabach, Bavaria 91126

0 studies enrolling now · 2 studies all time

What they study most

Pulmonary Disease, Chronic Obstructive

Studies at this site

• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD — Completed
• Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks — Completed